Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
This could be the revolutionary tool drug companies have been waiting for |
By MIT Tech Review |
| Mendelian randomization could help bypass large-scale clinical trials by focusing on the genetics of patients.
The backstory: For years, medical researchers have noted the presence of markers alongside certain traits. For instance, it’s known that a high presence of HDL is tied to a lower risk of heart attacks. But what wasn’t always known was whether the HDL caused the healthy heart, or was just correlated with it. The breakthrough: As Gary Taubes explains for us, researchers say that by employing innate genetic differences between people—an inborn susceptibility to alcohol, say, or to higher cholesterol levels in the arteries—they can now mimic, at much less effort and expense, the kinds of large trials that would be necessary to determine if an HDL-lowering medicine is really beneficial. Random facts: The new technique, called Mendelian randomization, is already being used by drug companies to make billion-dollar decisions about which drugs to pursue. |
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements.
Book Marcinko: https://medicalexecutivepost.com/dr-david-marcinkos-bookings/
Subscribe: MEDICAL EXECUTIVE POST for curated news, essays, opinions and analysis from the public health, economics, finance, marketing, IT, business and policy management ecosystem.
MORE FOR DOCTORS AND NURES:
“Insurance & Risk Management Strategies for Doctors” https://tinyurl.com/ydx9kd93
“Financial Management Strategies for Hospitals” https://tinyurl.com/yagu567d
“Operational Strategies for Clinics and Hospitals” https://tinyurl.com/y9avbrq5
***
Share this:
Filed under: iMBA, Inc. | Tagged: A Revolutionary New Drug Tool |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a Reply